Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · IEX Real-Time Price · USD
15.91
+0.17 (1.08%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Zai Lab Revenue
In the year 2023, Zai Lab had annual revenue of $266.72M with 24.03% growth. Revenue in the quarter ending December 31, 2023 was $65.83M with 5.16% year-over-year growth.
Revenue (ttm)
$266.72M
Revenue Growth
+24.03%
P/S Ratio
5.89
Revenue / Employee
$122,629
Employees
2,175
Market Cap
1.57B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
Dec 31, 2018 | 129.00K | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Addus HomeCare | 1.06B |
Myriad Genetics | 753.20M |
Warby Parker | 669.77M |
Taro Pharmaceutical Industries | 610.83M |
U.S. Physical Therapy | 604.80M |
UFP Technologies | 400.07M |
ADMA Biologics | 258.22M |
Avadel Pharmaceuticals | 27.96M |
ZLAB News
- 11 days ago - Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024 - Business Wire
- 15 days ago - Zai Lab Statement on Executive Management Team's Agreement on Share Activities - Business Wire
- 24 days ago - Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs - Business Wire
- 25 days ago - Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic - Business Wire
- 4 weeks ago - Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors - Business Wire
- 7 weeks ago - Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) - Business Wire
- 7 weeks ago - Zai Lab Announces Participation in March Investor Conference - Business Wire